Quantitative Contribution of CD4 and CD8 to T Cell Antigen Receptor Serial Triggering

By Antonella Viola,* Mariolina Salio,* Loretta Tuosto,† Susanne Linkert,* Oreste Acuto,‡ and Antonio Lanzavecchia*†

Summary

CD4 and CD8 are thought to function as coreceptors by binding to the cognate major histocompatibility complex (MHC) molecule recognized by the T cell antigen receptor (TCR) and initiating the signal transduction cascade. We report that during T cell–antigen-presenting cell interaction, triggered TCRs and coreceptors are downregulated and degraded with identical kinetics. This coordinated disappearance takes place whenever the TCR is triggered, even when the coreceptor does not engage the cognate MHC molecule and is the consequence of binding of the coreceptor-associated Lck to ZAP-70. The interaction of coreceptor and cognate MHC molecules is dispensable when T cells are stimulated by optimal ligands, but becomes crucial when suboptimal ligands are used. In the latter case the coreceptor increases the efficiency of TCR triggering without changing the activation threshold or the quality of the T cell response.

Because of their capacity to bind to the same MHC molecule as that engaged by the TCR (1, 2), and because of their association with the tyrosine kinase Lck (3), CD4 and CD8 have been defined as coreceptors (4, 5). The binding of coreceptor to the cognate MHC molecule is thought to perform two functions: (a) to stabilize the TCR–peptide MHC interaction (6–8); and (b) to carry Lck in contact with the TCR to initiate phosphorylation events (9). Indeed, cross-linking of TCRs and coreceptors results in enhanced T cell response (10, 11), whereas interference with the coreceptor–MHC interaction inhibits T cell activation or changes the quality of the response (12–14).

However, there are clear cases where the interaction of coreceptors with cognate MHC molecules appears to be dispensable for full T cell activation (15). These findings raise the question of whether the contribution of the coreceptor to T cell activation is qualitative, in the sense that it provides signals additional to and different from those provided by TCR alone, or whether the coreceptor acts by facilitating the triggering of TCRs when the interaction has lower than optimal kinetics.

We report that during T cell–APC interaction, the coreceptors are recruited to triggered TCRs and are downregulated with identical kinetics, even when the coreceptor does not engage the cognate MHC molecule. This process is the consequence of the binding of coreceptor-associated Lck to ZAP-70/ζ and takes place whenever the TCR is triggered. We also show that the contribution of the coreceptors becomes crucial when suboptimal ligands are used.

In this case, engagement of the coreceptor with the cognate MHC molecule increases the efficiency of serial TCR triggering without changing the activation threshold or the quality of the T cell response.

Materials and Methods

T Cell Clones. HLA-DR1101-restricted (KS140, KS70, and KS164) and DR1302-restricted (AL15.1) CD4+ T cell clones specific for tetanus toxin (TT)30–84 peptide and HLA-A2-restricted CD8+ clones (CER22, CER43) specific for the influenza matrix (M) 58–66 peptide were used. T cell clones were conjugated with EBV-transformed B (EBV-B) cells pulsed with various concentrations of either peptide or bacterial superantigens (toxic shock syndrome toxin or staphylococcal enterotoxin B) or monovalent anti-CD3 antibodies (W632/T3 or L243/T3) as described (16). CD4+CD8+ alloreactive T cell clones were isolated by sorting double positive cells from a primary MLR. CD8+ alloreactive T cell clones that recognize class II molecules on the class I− EBV-B .221 cells were generated, stimulated PBM C with irradiated .221 cells, followed by sorting and cloning of the CD8+CD4− cells. The class II specificity of the clones was verified using a panel of typed EBV-B cells as well as inhibition by anti-class II antibodies.

FACS Analysis. T cells were conjugated with autologous EBV-B cells pulsed with peptide, superantigen, or anti-CD3 for 5 h at 37°C. Downregulation and degradation of TCR/CD3 and coreceptors were measured by indirect immunofluorescence on intact and permeabilized cells as previously described (17, 18) using antibodies to CD3 (OKT3 or Leu3a), CD4 (6D10), and CD8 (OKT8). The absolute numbers of CD3, CD4, and CD8 molecules per cell were estimated by reference to a standard curve of...
beads coated with known amounts of mouse Ig (Flow Cytometry Standards Europe, Leiden, The Netherlands).

Immunoprecipitations and kinase assays. T cells were stimulated or not with the appropriate APC for 2 min at 37°C and lysed for 30 min at 4°C in 1% TritonX-100 buffer (20 mM Tris.HCl, pH 7.5, 150 mM NaCl, 1 mM MgCl₂, and 1 mM EDTA) in the presence of protease and phosphatase inhibitors (10 μg/ml aprotonin, 10 μg/ml leupepton, 1 mM Pefabloc-SC, 50 mM NaF, 10 mM Na₃P₂O₇, and 1 mM NaVO₄). CD4 immunoprecipitation, in vitro kinase assay, and reimmunoprecipitation with anti–ZAP-70 or anti-ζ were performed as previously described (19, 20) using the following antibodies: 19Thy-5D7 (IgG2a, anti-CD4), 21Thy-2D3 (IgG1, anti-CD8), and rabbit polyclonal antibodies to ZAP-70 and ζ.

Drugs and Transfection. Genistein and herbimycin A were purchased from Calbiochem (La Jolla, CA) and used as previously described (21). After overnight treatment with herbimycin, which is required to deplete Lck, the expression of coreceptor was reduced by ~50%. cDNAs encoding wild-type human CD4 and the mutant CD4.401 molecule that does not associate with Lck were a gift of Dr. Dan Littman (Skirball Institute of Biomolecular Medicine, NYU Medical Center, New York; reference 22). The cDNA was subcloned in the pSAM-EN retroviral vector (23) using the SalI–XhoI restriction sites. Plasmid DNA was purified and transduced in the amphotropic packaging cell line PA317 as previously described (22).

Substituted Peptides and Anti-coreceptor Antibodies. Several substituted analogs of TT830-843 were tested for their capacity to trigger T cell proliferation, and peptides with unaltered capacity to bind to DR molecules but weaker T cell stimulatory capacity were selected. Blocking anti-CD4 antibodies (M-T310, M-T413, M-T414, and M-T435) and anti-CD8 (733) were a gift of Dr. E.P. Rieber (Institute of Immunology, Technical University Dresden, Germany) and Dr. E. Roosnek (University Hospital, Geneva, Switzerland). Antibodies were used in the culture at 10 μg/ml.

Results

Parallel Downregulation and Degradation of the Coreceptor and TCR. To understand the contribution of the coreceptor to TCR triggering and T cell activation, we studied the TCR–coreceptor interaction in T cells stimulated by a specific ligand. It has been shown that, after triggering by agonists, TCRs are downregulated and degraded and this downregulation can be used to measure the number of TCRs triggered (17, 18). Therefore, we investigated whether the CD4 or CD8 coreceptors would also be downregulated together with the TCR. We observed that in specific T–APC conjugates, TCRs and coreceptors are downregulated with the same kinetics and with fixed stoichiometry (Fig. 1, A and B). In addition, downregulation is followed by rapid degradation of both coreceptor and TCR (Fig. 1 C). By reference to a standard curve of Ig-coated beads, we estimated that approximately two CD4 or four CD8 molecules are downregulated for each TCR (data not shown), an estimate which is consistent with that reported for CD4 by Saizawa and Janeway (24).

Intracellular Recruitment of Coreceptor to Triggered TCRs in the Absence of an Interaction with Cognate or Noncognate MHC Molecules. Downregulation of CD3 and coreceptor in CD4⁺ (KS70; A) or CD8⁺ (CER43; B) T cell clones stimulated by specific peptide-MHC (●), superantigens (□), or monovalent anti-CD3 antibodies: w632/T3 (△), L243/T3 (○). (C) Downregulation of CD3 versus CD4 (▲) and CD8 (○) in alloreactive CD4⁺ CD8⁺ T cell clones stimulated by specific allogeneic (D). Downregulation of CD3 and CD8 in CD8⁺, class II–alloreactive T cell clones stimulated with class I–APCs (●) expressing the relevant class II alloantigen.

Figure 1. Parallel downregulation and degradation of CD4 and CD8 together with CD3 in T cell clones stimulated by specific antigen. (A) Time course of CD3 (●) and CD4 (△) downregulation in clone KS140 stimulated with APCs pulsed with 10 nM TT830-842. (B) CD3 (●) and CD8 (○) downregulation in clone CER22 stimulated with APCs pulsed with 100 nM M58-66. (C) Surface and total levels of CD3 and CD4 as determined by staining before and after permeabilization in KS70 cells conjugated for 5 h with APCs un pulsed (empty bars) or pulsed with 0.1 μM (hatched bars) or 10 μM (filled bars) TT830-842.

Figure 2. Downregulation of coreceptors can occur in the absence of an interaction with cognate or noncognate MHC molecules. Downregulation of CD3 and coreceptor in CD4⁺ (KS70; A) or CD8⁺ (CER43; B) T cell clones stimulated by specific peptide-MHC (●), superantigens (□), or monovalent anti-CD3 antibodies: w632/T3 (△), L243/T3 (○). (C) Downregulation of CD3 versus CD4 (▲) and CD8 (○) in alloreactive CD4⁺ CD8⁺ T cell clones stimulated by specific allogeneic (D). Downregulation of CD3 and CD8 in CD8⁺, class II–alloreactive T cell clones stimulated with class I–APCs (●) expressing the relevant class II alloantigen.
specific ligand (Fig. 3). First, immunoprecipitation experiments showed that, as evidenced indicate that the downregulation of the coreceptor was next investigated. Three lines of evi-
dence show that the downregulation of the coreceptor was due to an intracellular association with triggered TCRs. (Fig. 3 B).

The mechanism responsible for the downregulation of the coreceptor was next investigated. Three lines of evidence indicate that the downregulation of the coreceptor was due to an intracellular association with triggered TCRs. First, immunoprecipitation experiments showed that, as previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by ant-icids (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-containing coreceptor, previously demonstrated in Jurkat cells activated by anti-CD3 antibodies (19, 20), a complex-cont
qualitatively different responses, we correlated TCR down-regulation and cytokine production in T cells stimulated by strong or weak agonists in the presence or absence of anti-CD4 antibodies. As shown in Fig. 5, the inhibition of T cell response by anti-CD4 antibodies precisely correlated with a reduced level of TCR downregulation both when strong and weak agonists were used. These results indicate that the anti-CD4 antibody mimics the effect of a weak agonist, i.e., results in a decreased efficiency of serial triggering. However, in spite of a decreased efficiency of TCR triggering, the threshold of T cell activation and the type of cytokines produced were not affected by anti-CD4. Indeed, T cells produced IFN-γ, IL-2, and TNF-α when ~20–30% of TCRs were triggered, irrespective of the strength of the agonist and of the presence or absence of anti-CD4. IL-3 production consistently required higher levels of TCR occupancy, which were comparable in all experimental conditions.

Discussion

Our results reconcile several apparently contradictory observations concerning coreceptor dependency and the role of extracellular and intracellular interactions in coreceptor function. We have shown that in T cells activated by peptide-MHC, superantigens, or anti-CD3 antibodies the coreceptors are recruited to triggered TCRs and are downregulated and degraded together with them. This process does not necessarily require the interaction of the coreceptor with the cognate MHC molecule, but takes place whenever the TCR is triggered via the intracellular association of Lck and ZAP-70/ζ.

It is interesting that even in unstimulated T cell clones ζ and ZAP-70 can be immunoprecipitated by anti-CD4 or anti-CD8 antibodies, although the complexes contain only low levels of kinase activity. This finding suggests that in human as well as mouse T cells a fraction of TCRs is constitutively associated with the coreceptor (26). This association may be responsible for the constitutive association of phospho-ζ and ZAP-70 observed in thymocytes and lymph node T cells (27). It is tempting to speculate that the constitutive association of TCR and coreceptors might play a role in inducing positive selection by self-ligands in the thymus as well as in facilitating the response to low-affinity ligands in periphery.

There is clear evidence that coreceptor can stabilize the TCR/peptide-MHC interaction (6–8). We have shown here that this stabilization may actually result in an increased rate of TCR triggering. Indeed, the coreceptor appears to be dispensable when the ligands have optimal kinetics, allowing efficient serial TCR triggering. However, the binding of coreceptor to cognate MHC molecules becomes critical in the case of low-affinity ligands because in this case the coreceptor can initially stabilize the TCR-ligand interaction, thus increasing the probability that an engagement event will result in triggering.

Our results also show that coreceptors play a quantitative role in T cell activation. Indeed the reduced response observed in cultures stimulated with suboptimal ligands or in the presence of anticoreceptor antibodies can be fully accounted for by a reduced level of TCR triggering. The fact that the T cell activation thresholds and the profile of cytokines produced are comparable in all conditions of stimulation is not surprising. Indeed, in all cases the triggered TCRs have been shown to be complexed with coreceptors, suggesting similar composition and transduction capacity of the signaling complexes.
We thank E.P. Rieber and E. Roosnek for providing blocking anti-CD4 and anti-CD8 antibodies, D. Littmann for providing CD4 constructs, and K. Karjalainen and M. Cella for critical reading and comments.

The Basel Institute for Immunology was founded and is supported by F. Hoffmann La Roche Ltd., Basel, Switzerland.

Address correspondence to Antonella Viola, Basel Institute for Immunology, Grenzacherstrasse 487, CH 4005, Basel, Switzerland. Phone: 41-61-605-1210; FAX: 41-61-605-1222; E-mail: viola@bii.ch

Received for publication 9 July 1997 and in revised form 12 September 1997.

References

1. Doyle, C., and J.L. Strominger. 1987. Interaction between CD4 and class II MHC molecules mediated cell adhesion. Nature (Lond.). 330:256–259.

2. Norment, A.M., R.D. Salter, P. Parham, V.H. Engelhard, and D.R. Littman. 1988. Cell–cell adhesion mediated by CD8 and MHC class II molecules. Nature (Lond.). 336:79–81.

3. Veillette, A., M.A. Bookman, E.M. Horak, and J.B. Bolen. 1988. The CD4 and CD8 T-cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell. 55:301–308.

4. Janeway, C.A., Jr. 1987. Interaction between CD4 and class II MHC molecules mediated cell adhesion. Nature (Lond.). 330:256–259.

5. Janeway, C.A., Jr. 1991. The co-receptor function of CD4. Semin. Immunol. 3:153–160.

6. Luescher, I.F., E. Vivier, A. Layer, J. Mahiou, F. Godeau, B. Malissen, and P. Romero. 1995. CD8 modulation of T cell antigen receptor–ligand interactions on living cytotoxic T lymphocytes. Nature (Lond.). 373:353–356.

7. Renard, V., P. Romero, E. Vivier, B. Malissen, and I.F. Luescher. 1996. CD8β increases CD8 co-receptor function and participation in TCR–ligand binding. J. Exp. Med. 184:2439–2444.

8. Garcia, K.C., C.A. Scott, A. Brunmark, F.R. Carbone, P.A. Peterson, I.A. Wilson, and L. Teyton. 1996. CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes [see comments]. Nature (Lond.). 384:577–581.

9. Weiss, A., and D.R. Littman. 1994. Signal transduction by the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature (Lond.). 334:162–165.

10. Candotti, F., S.A. Oakes, J.A. Johnston, L.D. Notarangelo, I.A. Wilson, and L. Teyton. 1996. CD8 enhances viral-mediated gene transduction. Proc. Natl. Acad. Sci. USA. 83:8298–8302.

11. Janeway, C.A., Jr., and K. Bottomly. 1994. Signals and signs for lymphocyte responses. Cell. 76:275–285.

12. Madrenas, J., L.A. Chau, J. Smith, J.A. Bluestone, and R.N. Germain. 1997. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide–MHC molecule ligands. J. Exp. Med. 185:219–229.

13. Vidal, K., B.L. Hsu, C.B. Williams, and P.M. Allen. 1996. Endogenous altered peptide ligands can affect peripheral T cell responses. J. Exp. Med. 183:1311–1321.

14. Manning, M.D., J.M. Roser, and G.A. White. 1995. Autologous rat myelin basic protein is a partial agonist that is converted into a full agonist upon blockade of CD4. Evidence for the integration of efficacious and nonefficacious signals during T cell antigen recognition. J. Immunol. 154:2642–2654.

15. Cerundolo, V., A.G. Tse, R.D. Salter, P. Parham, and A. Townsend. 1991. CD8 independence and specificity of cytoxic T lymphocytes restricted by HLA-Aw68.1. Proc. R. Soc. Lond. B. Biol. Sci. 244:169–177.

16. Viola, A., and A. Lanzavecchia. 1996. T cell activation determined by T cell receptor number and tunable thresholds [see comments]. Science (Wash. DC). 273:104–106.

17. Valitutti, S., S. Muller, M. Cella, E. Padovan, and A. Lanzavecchia. 1995. Serial triggering of many T cell receptors by a few peptide–MHC complexes [see comments]. Nature (Lond.). 375:148–151.

18. Valitutti, S., S. Muller, M. Salio, and A. Lanzavecchia. 1997. Degradation of T cell receptor (TCR)–CD3-ζ complexes after antigen stimulation. J. Exp. Med. 185:1859–1864.

19. Thome, M., P. Duplay, M. Guttinger, and O. Acuto. 1995. Syk and ZAP-70 mediate recruitment of p56lck/CD4 to the activated T cell receptor–CD3-ζ complex. J. Exp. Med. 181:1997–2006.

20. Thome, M., V. Germain, J.P. DiSanto, and O. Acuto. 1996. The p56lck SH2 domain mediates recruitment of CD8β p56lck to the activated T cell receptor/CD3-ζ complex. Eur. J. Immunol. 26:2093–2100.

21. Salio, M., S. Valitutti, and A. Lanzavecchia. 1997. Agonist-induced TCR downregulation: molecular requirements and dissociation from T cell activation. Eur. J. Immunol. 27:1769–1773.

22. Bedinger, P., A. Mordiny, R.C. von Borstell II, N.J. Donovan, K.S. Stermer, and D.R. Littman. 1988. Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature (Lond.). 334:162–165.

23. Rand, D., J.A. Johnston, L.D. Notarangelo, J.J. O’Shea, and R.M. Blaese. 1996. In vitro correction of Jak3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction. J. Exp. Med. 183:2687–2692.

24. Saizawa, K., and C.A. Janeway, Jr. 1987. Evidence for a physical association of CD4 and the CD3ζβ T-cell receptor. Nature (Lond.). 328:260–263.

25. Valitutti, S., and A. Lanzavecchia. 1997. Serial triggering of T-cell receptors: a basis for the sensitivity and specificity of T cell antigen recognition. Immunol. Today. 18:299–304.

26. Díez-Orejas, R., S. Ballester, M.J. Feito, G. Criado, M. Ronda, P. Portoles, and J.M. Rojo. 1994. Genetic and immunohistochemical evidence for CD4-dependent association of p56lck with the αβ T-cell receptor (TCR): regulation of TCR-induced activation. EMBO (Eur. Mol. Biol. Organ.). 13:90–99.

27. van Oers, N.S.C., N. Killeen, and A. Weiss. 1994. ZAP-70 is constitutively associated with tyrosine-phosphorylated TCR ζ in murine thymocytes and lymph node T cells. Immunity. 1:675–685.